Loading companies…
Canada · Healthtech
AI software that analyzes medical imaging from clinical trials to measure treatment response and predict outcomes.
Altis Labs’ IPRO model analyzes CT scans already collected in clinical trials and generates imaging-based measures, including predictions of patient survival. In a post-hoc analysis of the MARIPOSA Phase 3 trial, the company reported that its response measure detected a treatment effect ahead of later progression-free and overall-survival readouts. The Series A supports continued development of these AI endpoints.
| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series A | $25M | Benchstrength — ParticipantFusion Fund — ParticipantInnovation Endeavors — ParticipantLumira Ventures — Participant |